ProQuad MMRV
Selected indexed studies
- MMRV vaccine safety. (Vaccine, 2019) [PMID:29526373]
- Vaccines for travelers. (Med Lett Drugs Ther, 2018) [PMID:30625125]
- Analysis of safety data in children after receiving two doses of ProQuad® (MMRV). (Vaccine, 2014) [PMID:25219563]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- MMRV vaccine safety. (2019) pubmed
- MMRV vaccine safety: A comprehensive analysis of adverse events recorded among pediatric populations. (2025) pubmed
- Infantile Sweet syndrome following MMRV vaccine. (2023) pubmed
- Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials. (2015) pubmed
- A systematic review and meta-analysis of adverse events following measles-containing vaccines in infants less than 12 months of age. (2025) pubmed
- Vaccines for travelers. (2018) pubmed
- Analysis of safety data in children after receiving two doses of ProQuad® (MMRV). (2014) pubmed
- Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (Infanrix-hexa®) and MMRV (ProQuad®) at 18 months of age. (2018) pubmed
- Adverse events following measles, mumps, rubella and varicella virus vaccine live (PROQUAD(®)) reported to the vaccine adverse event reporting system (VAERS), 2015-2025. (2025) pubmed
- Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. (2014) pubmed